跳至主要内容
临床试验/NCT04530409
NCT04530409进行中(未招募)4 期

Timing of Corticosteroids in COVID-19, II. Post COVID-19 Follow-up

ClinAmygate1 个研究点 分布在 1 个国家目标入组 752 人开始时间: 2021年3月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
进行中(未招募)
发起方
入组人数
752
试验地点
1
主要终点
Percentage of cases that will need oxygen supplementation

研究概览

简要总结

Timing of of corticosteroids administration is very important in COVID19 cases for the recovery and decrease the mortality.

详细描述

The sickest patients with COVID-19 suffer a hyperinflammatory state-a cytokine storm-that has features in common with a rare haematological condition called haemophagocytic lymphohistiocytosis. Immune suppression should help such patients. By contrast, immune suppression during the early phase of the viral infection might allow increased viral replication and aggravate the disease.

The 3C-like proteinase on SARS-CoV-2 (nsp5) inhibits HDAC2 transport into the nucleus, and so impairs the way in which it mediates inflammation and cytokine responses, so activation of histone deacetylase by dexamethasone may directly oppose the action of SARS-CoV-2.

Timing of of corticosteroids administration is very important in COVID19 cases for the recovery and decrease the mortality.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • any case with COVID-19 more than or equal to 18 years
  • mild and moderate severity

排除标准

  • Severe to critical COVID-19
  • Any contra-indication for the interventional drug
  • Mentally disabled cases

研究组 & 干预措施

Early CS

Experimental

early use of dexamethasone as early as the laboratory confirmation of inflammation.

干预措施: Early-Corticosteroids (Drug)

结局指标

主要结局

Percentage of cases that will need oxygen supplementation

时间窗: 10 days

Percentage of cases whose clinical status deteriorate that their sPO2 become less than 92%

Percentage of cases that will need hospitalization

时间窗: 10 days

Deterioration in the clinical picture of cases that necessitate hospitalization

28-days mortality

时间窗: 28 days

Percentage of cases who died within 28 days of presentation

次要结局

  • Percentage of cases with increased d-dimer(10 days)
  • Percentages of COVID-19 Severity according to CDC 2020(10 days)
  • Time to return to daily activity(60 days)
  • Percentage reduction in LDH(10 days)
  • Percentage reduction in CRP(10 days)
  • Percentage reduction in Ferritin(10 days)

研究者

发起方
ClinAmygate
申办方类型
Other
责任方
Principal Investigator
主要研究者

Emad R Issak

Dr

ClinAmygate

研究点 (1)

Loading locations...

相似试验